These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22129316)

  • 21. Sildenafil for erectile dysfunction in the Middle East: observational analysis of patients with diabetes and/or hypertension treated in the clinical practice setting.
    El-Sakka AI; Anis T; Khadr N; Ismail TA; Hegazy AM; Fekry O; Youseif E
    J Int Med Res; 2011; 39(2):558-68. PubMed ID: 21672361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
    Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
    J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature.
    Azzouni F; Abu samra K
    J Sex Med; 2011 Oct; 8(10):2894-903. PubMed ID: 21771280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advances in application of sildenafil to erectile dysfunction].
    Li Z; Wu ZM; Wang YX
    Zhonghua Nan Ke Xue; 2005 Jun; 11(6):473-6. PubMed ID: 15999498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does sildenafil cause myocardial infarction or sudden cardiac death?
    Kontaras K; Varnavas V; Kyriakides ZS
    Am J Cardiovasc Drugs; 2008; 8(1):1-7. PubMed ID: 18303932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Update of PDE5 inhibitors as treatment of ED].
    Lu YN; Chen B
    Zhonghua Nan Ke Xue; 2005 Jul; 11(7):552-5. PubMed ID: 16078679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil.
    Dadkhah F; Safarinejad MR; Asgari MA; Hosseini SY; Lashay A; Amini E
    Int J Impot Res; 2010; 22(1):51-60. PubMed ID: 19865092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of sildenafil in melanoma incidence and mortality.
    Robinson JK
    JAMA Intern Med; 2014 Jun; 174(6):970-1. PubMed ID: 24710720
    [No Abstract]   [Full Text] [Related]  

  • 30. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
    Scranton RE; Goldstein I; Stecher VJ
    J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.
    Rubio-Aurioles E; Porst H; Eardley I; Goldstein I
    J Sex Med; 2006 Nov; 3(6):1037-1049. PubMed ID: 17100937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of sildenafil in the treatment of erectile dysfunction in patients with obstructive sleep apnoea.
    Perimenis P; Giannitsas K
    Expert Opin Drug Saf; 2007 Jul; 6(4):423-30. PubMed ID: 17688386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the association between erectile rigidity and treatment adherence with sildenafil.
    Mazzola CR; Deveci S; Teloken P; Mulhall JP
    J Sex Med; 2013 Jul; 10(7):1861-6. PubMed ID: 23253943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P144, A TGF-β1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats.
    Li WJ; Wang H; Zhou J; Li B; Zhang J; Lu M; Wang Z
    J Sex Med; 2013 Dec; 10(12):2942-51. PubMed ID: 24134744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can an educational program optimize PDE5i therapy? A study of Canadian primary care practices.
    Brock G; Carrier S; Casey R; Tarride JE; Elliott S; Dugré H; Rousseau C; D'Angelo P; Defoy I
    J Sex Med; 2007 Sep; 4(5):1404-13. PubMed ID: 17634053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
    Agarwal P; Sander GE; Giles TD
    Am J Geriatr Cardiol; 2004; 13(6):332-5. PubMed ID: 15538074
    [No Abstract]   [Full Text] [Related]  

  • 37. Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process.
    Vicari E; La Vignera S; Condorelli R; Calogero AE
    J Sex Med; 2010 Mar; 7(3):1247-53. PubMed ID: 19674252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaza and sildenafil: comparison of clinical effectiveness in patients with erectile dysfunction.
    Petrov VI; Vekel'yan AS; Martyushev AV; Sergeeva SA; Smolenov IV; Epstein OI
    Bull Exp Biol Med; 2003 Jan; 135 Suppl 7():150-1. PubMed ID: 12949684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Optimization of the use of phosphodiesterase-5 inhibitors].
    Pushkar' DIu; Segal AS
    Urologiia; 2012; (4):79-80, 82. PubMed ID: 23116030
    [No Abstract]   [Full Text] [Related]  

  • 40. [A decade's evidence review of sildenafil citrate].
    Zhang K; Zhu JC
    Zhonghua Nan Ke Xue; 2009 Jan; 15(1):3-6. PubMed ID: 19288739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.